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Abstract. Aim: This paper establishes the prevalence of chemsex drug use amongst men who have sex 
with men (MSM), the extent to which these drugs are used in a sexual context, as well as their associated 
behaviours and circumstances of use. Methods: Data from a cross-sectional, online survey of 2428 MSM 
recruited via gay sociosexual media in Scotland, Wales, Northern Ireland and the Republic of Ireland were 
analysed. Results: Whilst almost half (48.8%) of participants had ever taken illicit drugs, lifetime chemsex 
drug use was less common (18.0%) and far fewer reported chemsex drug use in the last year (8.2%) or last 
4 weeks (3.0%). One quarter (27.1%) of men who used chemsex drugs in the last year reported no 
sexualized drug use, but almost three-quarters (72.9%) did. Only 6.1% of the whole sample reported 
sexualized chemsex drug use in the last year. The odds of reporting chemsex in the last year were 
significantly higher for men aged 36–45 (AOR = 1.96), single men (AOR = 1.83), men who were HIV 
positive (AOR = 4.01), men who report high risk sex (AOR = 4.46), being fisted (AOR = 7.77), or sex in 
exchange for goods other than money (AOR = 4.7) in the last year and men who reported an HIV test in the 
last 3 months (AOR = 1.53). Discussion: Only a small proportion of MSM in these four countries reported 
chemsex, and, for the first time, we demonstrate that not all chemsex drug use was sexualized. 
Nevertheless, MSM who engage in chemsex (MWEC) reported substantial sexual risk inequalities. These 
novel findings highlight several opportunities for intervention, particularly around the multiple 
vulnerabilities of MWEC, opportunities for early identification of those most vulnerable to chemsex-related 
harm and the potential to develop a specialised responsive patient pathway. 
Introduction 
‘Chemsex’, the use of drugs in sexual settings amongst men who have sex with men (MSM), 
has received sustained attention in the United Kingdom (UK) for the last five years. Chemsex in 
this geographic context is typically associated with the use of mephedrone, crystal 
methamphetamine, ketamine and/or gamma-hydroxybutrate (GHB) or the pre-drug gamma-
butyrolactone (GBL)1,2. Qualitative research from London highlights a range of psychological, 
social and relational harms associated with chemsex, as well as a propensity for overdose3. 
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Indeed, data from the coroner of England & Wales indicates a 119% rise in GHB/GBL overdose 
related deaths between 2014 and 2015, with an individual dying every 12 days, is potentially 
linked to chemsex4. 
Further to this, sexual health harms have been widely examined, with several clinic-based 
studies indicating an increased likelihood of having been diagnosed with a sexually transmitted 
infection (STI) within the previous 6 or 12 months among those who had used one or more of the 
drugs associated with chemsex5,6. Commonly reported effects of these drugs include heightened 
sexual arousal, increased longevity of sex and, as a consequence, an increased potential for higher 
number of sexual partners7. Several studies have found illicit drug use, especially crystal 
methamphetamine use, to be associated with unprotected anal intercourse at both the individual8 
and event levels9. However, not all studies report this finding and care must be taken in assuming 
causal pathways10,11. With a significant proportion of men engaging in chemsex already living 
with diagnosed HIV, and who largely report anti-retroviral therapy adherence12,13, the potential 
for HIV transmission within chemsex environments is less certain, but still possible. In addition, 
the potential for toxic drug interactions to negatively impact HIV clinical outcomes is emerging 
and multifaceted14. 
Despite sustained media interest in the topic15,16, there are limited data to inform estimates on 
the prevalence of chemsex among men who have sex with men anywhere in the British Isles, and 
little quantitative data to inform understandings of associated sexual behaviours. Such estimates 
are critically important for planning services (e.g. specialised interventions for harm reduction) 
and allocating resources where they are needed most (e.g. chemsex intervention v. partner 
notification work). While there have been a variety of papers describing findings from clinical 
audits or involving clinical samples17-19, these may recruit a disproportionate proportion of men 
engaging in riskier behaviours and who recognise a need for health care engagement. An 
exception within the British Isles context comes in the Gay Men’s Sex Survey12, which reports 
overall prevalence of chemsex among MSM living in England (but does not include the other 
countries within the British Isles) of 6.6%. However, this measure accounts for all contexts in 
which these drugs are used and does not specifically indicate whether they were used in a sexual 
context. 
This paper aims to establish prevalence of the use of drugs associated with chemsex, and for 
the first time, the extent to which they are actually used in a sexual context, as well as determine 
the associated behaviours and circumstances of use. Such data will be of use to those planning 
service provision, those designing and delivering sexual health promotion and harm reduction 
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interventions in diverse settings. With no data from the last five years focusing on countries or 
nations of the British Isles other than England, here we focus on gay, bisexual and other MSM 
living in Scotland, Wales, Northern Ireland (NI) and the Republic of Ireland (RoI). 
Methods 
Population, sampling and recruitment 
The Social Media, MSM and Sexual and Holistic Health (SMMASH2) survey collected 
anonymous, self-complete questionnaires from men recruited online via gay-specific sociosexual 
media websites (Gaydar, Recon and Squirt) and smartphone apps (Gaydar, Recon, Grindr, Growlr 
and Hornet) between April and June 2016. All members of these sociosexual media whose i) 
profile location, ii) computer IP address or iii) smartphone GPS coordinates were located in 
Scotland, Wales, NI or RoI, were invited to participate as follows; each profile was sent two 
message blasts (either as a pop-up message [Gaydar, Recon, Grindr, Growlr and Squirt] or an 
inbox message [Hornet]) asking them to participate in our survey. In addition, banner 
advertisements, designed to fit the character of each website/app, were employed to advertise the 
survey on Gaydar, Recon, Grindr, Growlr, Hornet and Squirt. Clicking on the message blast or 
banner ad took participants to our survey landing page, which provided full details of the survey, 
highlighting they were under no obligation to take part and that participation was taken as 
evidence of consent. No financial incentive was given and participants were asked not to 
complete the questionnaire if they had already done so, but duplicates were not screened for. 
Fraudulent and partial entries were screened and deleted. Participants were provided with details 
of local sexual and mental health services online upon survey completion or exit. Each site/app 
has a minimum user age of 18, but some men aged 16–17 did participate. In total, 3217 men 
completed useable questionnaires. 
Survey content 
Questionnaires surveyed demographics (age, ethnicity, sexual orientation, educational 
qualifications, relationship status and financial worries), sexual health indicators (HIV testing and 
status), commercial sex experience and various sexual behaviours in the previous 12 months. A 
measure of condomless anal intercourse (CAI) with higher risk for HIV infection was derived to 
include men who reported CAI with  2, casual, and/or HIV status unknown/serodiscordant 
partners in the previous 12 months (compared with men reporting CAI with 0/1, regular and/or 
HIV status known/seroconcordant partners only). These measures were developed and used 
previously in the MRC Gay Men’s Sexual Health Survey20 and SMMASH study21. Participants 
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were also asked questions about their use of illicit drugs (adapted from EMIS13), including 
lifetime experience of illicit drug use (defined here as ‘e.g. cannabis, ecstasy, cocaine etc.’) and 
when they last used crystal methamphetamine, mephedrone, GHB/GBL and ketamine 
respectively, the main 4 chemsex drugs (known colloquially as ‘chems’). Men who reported 
chemsex drug use in the last year, were also asked, ‘In the last 12 months, how much of the sex 
you've had was after taking [drug]’ for each of these 4 chemsex drugs, with responses on a 7 
point likert scale ranging from ‘None of it’ to ‘All of it’. 
Ethical approval was granted by Glasgow Caledonian University School of Health and Life 
Sciences Ethics Subcommittee (HLS id: HLS/NCH/15/26) and consent assumed by survey 
participation. 
Analyses 
Quantitative data were analysed with IBM SPSS 23 for Mac by the first author. Only men who 
answered questions about their lifetime drug use were included in this analysis (n = 2428), of 
whom half (51.2%, n = 1193) had never taken illicit drugs and half (48.8%, n = 1135) had. Chi-
square tests and univariate logistic regression were used for bivariate comparisons. Variables 
significant at the bivariate level (P < 0.05) were block entered into a multivariate logistic 
regression model to estimate the adjusted odds ratios (AOR) and 95% confidence intervals (CI) 
for reporting chemsex in the last year. Here we define ‘chemsex’ as reporting having at least 
some sex after taking a chemsex drug (crystal methamphetamine, mephedrone, GHB/GBL or 
ketamine) in the last year. 
Results 
Sample demographics, sexual behaviours and HIV testing 
The characteristics of survey participants are shown in Table 1. Almost half of participants 
were recruited in Scotland, one quarter in RoI, with fewer in Wales and NI. The mean age of 
participants was 41 years (range 16–78, sd = 13.5), 97.3% were white and whilst most (81.9%) 
were gay identified, one in six were bisexual (17.2%) and several identified as straight (0.7%) or 
‘other’ (0.2%). Around 1 in 20 (5.7%) identified as transgender. Almost two-thirds (62.7%) had a 
degree or postgraduate level education. Over half (61.1%) were single, but 29.7% had a regular 
male partner (including same sex marriage and civil partnerships) and 9.2% had a regular female 
partner (including opposite sex marriage). Just under half (42.4%) said they had financial worries 
(sometimes, most, or all of the time). Most (82.3%) said they used the commercial gay scene (i.e. 
gay bars, clubs and saunas) once a month or less, with over half (51.4%) saying they never did. 
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Overall, 92.0% were either HIV negative or untested, and 8.0% said they had tested HIV positive. 
Just over one third (36.2%) report high risk CAI, 6.7% said they had been fisted and 29.6% had 
attended a sex party / had group sex in the last year, respectively. A small proportion of men 
reported sex in return for money (2.4%) or ‘anything else’ (1.5%) in the last year. Half (50.5%) 
reported an HIV test in the last year and almost one quarter (22.2%) reported an HIV test in the 
last 3 months. 
Table 1. Survey Sample Demographics, Sexual Behaviours and HIV testing (n = 2328) 
 n % 
Country of Recruitment   
Scotland 1131 48.6 
Wales 389 16.7 
NI 176 7.6 
RoI 632 27.1 
Missing 0  
Age   
18 - 25 374 16.1 
26 - 35 491 21.2 
36 - 45 549 23.7 
 >  = 46 906 39.1 
Missing 8  
Ethnicity   
White 2260 97.3 
Black 4 0.2 
Asian 11 0.5 
Mixed / Other 47 2.0 
Missing 6  
Sexual Orientation   
Gay 1890 81.9 
Bisexual 398 17.2 
Straight 17 .7 
Other 4 .2 
Missing 19  
Gender Identification   
Transgender 131 5.7 
Male 2165 94.3 
Missing 32  
Highest Qualification   
  Age 18 or equivalent 854 37.3 
University Degree or equivalent 1056 46.2 
Postgraduate degree or higher 377 16.5 
Missing 41  
Relationship Status   
Single 1417 61.1 
Regular Male Partner 690 29.7 
Regular Female Partner 213 9.2 
Missing 8  
Do you have any financial worries?   
Occasionally or never 1338 57.6 
Sometimes, most or all of the time 984 42.4 
Missing 6  
Commercial Gay Scene Use   
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  Twice a month 389 16.8 
Once a month or never 1932 83.2 
Missing 7  
HIV Status   
HIV+ 183 8.0 
HIV-/Unknown 2104 92.0 
Missing 41  
Report High Risk CAI   
No 1468 63.8 
Yes 833 36.2 
Missing 27  
Have you been fisted in the last year?   
No 2171 93.3 
Yes 155 6.7 
Missing 2  
Have you been to a sex party / had group sex in the last year?   
No 1634 70.4 
Yes 688 29.6 
Missing 6  
Have you received money in return for sex in the last year?   
No 2243 97.6 
Yes 54 2.4 
Missing 31  
Have you had sex with someone in return for anything else (like 
cigarettes, drugs, food etc.) in the last year? 
  
No 2288 98.5 
Yes 34 1.5 
Missing 6  
HIV test in the last year?   
No (includes never tested) 1141 49.5 
Yes 1165 50.5 
Missing 22  
HIV test in the last 3 months?   
No (includes never tested) 1793 77.8 
Yes 513 22.2 
Missing 22  
Illicit Drug use amongst MSM; individual and event level analysis 
Participants’ illicit drug use is shown in Table 2. Whilst almost half of participants had taken 
any illicit drugs in their lifetime (e.g. cannabis, ecstasy, cocaine etc.), lifetime chemsex drug use 
was far less common (crystal methamphetamine 5.1%; mephedrone 9%; GHB/GBL 10%; 
ketamine 11.5%) and fewer still reported using these drugs within the last year (crystal 
methamphetamine 2.5%; mephedrone 4.5%; GHB/GBL 4.9%; ketamine 3.8%). Only a small 
proportion of men ( 2% per drug) reported using any of these chemsex drugs in the last 4 weeks. 
In concert, whilst 18% (n = 435) of participants had used any chemsex drugs in their lifetime, 
only 8.2% (n = 198) had used them in the last year and just 3.0% (n = 72) had used them in the 
last 4 weeks. 
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In relation to event based sexualized drug use, we assessed the proportion of sexual events that 
incorporated the use of chemsex drugs. We asked those men who reported use of each chemsex 
drug in the last year what proportion of the sex they had had was after taking each drug, 
respectively. Combining these measures we found that of the men who report any chemsex drug 
use in the last year, one quarter (27.1%, n = 55) reported no sex on chemsex drugs, almost half 
(46.2%, n = 91) said less than half of their sex was after taking chemsex drugs and one quarter 
(25.9%, n = 51) said that half or more of their sex was after taking chemsex drugs. Thus for the 
whole sample of men in this study, 6.1% reported chemsex and 93.9% reported no chemsex in the 
last year. Stratifying this further, for the whole sample, most participants reported no chemsex 
drug use in the last year (91.7%, n = 2186), 2.3% (n = 55) reported non-sexual chemsex drug use 
only, 3.8% (n = 91) said that less than half of their sex was chemsex and 2.1% (n = 51) said that 
most of their sex was chemsex. Finally, a small proportion of men reported ‘slamming’ (injecting 
drugs themselves or by another person) chemsex drugs at sex parties in the last year (n = 30, 
1.3%); although this represents 21% of those men who reported any chemsex in the last year. 
Table 2. Use of Illicit Drugs and Chemsex Drugs 
 n %     
Have you ever taken illicit drugs?       
No 1193 51.2     
Yes 1135 48.8     
       
Have you taken the following drugs … Lifetime In the last year? In the last 4 weeks? 
Crystal Methamphetamine n % n % n % 
No 2270 94.9 2332 97.5 2369 99.0 
Yes 122 5.1 60 2.5 23 1.0 
Mephedrone       
No 2197 91.0 2306 95.5 2367 98.0 
Yes 218 9.0 109 4.5 48 2.0 
GHB/GBL       
No 2170 90.0 2293 95.1 2361 98.0 
Yes 241 10.0 118 4.9 50 2.0 
Ketamine       
No 2138 88.4 2323 96.2 2383 98.6 
Yes 278 11.6 93 3.8 33 1.4 
       
Have you taken any Chemsex Drugs? n %     
Never 1977 82.0     
In last Year 198 8.2     
> 1 year ago 237 9.8     
Any Chemsex in the last year? 
No 2186 93.9     
Yes 142 6.1     
What proportion of your sex was after taking Chemsex drugs? (amongst 197 men who report Chemsex drug use) 
None 55 27.1     
Less than half 91 46.2     
More than half 51 25.9     
How recently have you injected drugs, or had someone inject you with them, at a sex party? 
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Never 2298 98.7     
In the last year 30 1.3     
Characteristics of men who report chemsex in the last year 
We examined the characteristics of men who do and do not report chemsex in the last year (see 
Table 3). When controlling for the factors significant at the bivariate level in the multivariate 
regression analysis1, the adjusted odds of the likelihood of reporting chemsex in the last year were 
significantly higher for men aged 36–45 compared to 46+ (AOR = 1.96), single men (AOR = 
1.83), men who report high risk CAI (AOR = 4.46), men who said they were fisted in the last 
year (AOR = 7.77), men who reported sex in exchange for goods other than money (e.g. 
cigarettes, drugs, food etc.) (AOR = 4.7), men who were HIV positive (AOR = 4.01) and men 
who reported an HIV test in the last 3 months (AOR = 1.53). 
Table 3. Factors associated with reporting Chemsex in the last year. 
ns = non-significant, * < 0.05, **P < 0.01, *** < 0.001 
 No Chemsex (n = 
2186, 93.9%) 
Chemsex (n = 142, 
6.1%) 
Bivariate Regression 
Analyses 
Multivariate Regression 
Analyses (n = 2210) 
 n (%) n (%) OR (95% CI) AOR (95% CI) 
Country 
Scotland 1065 (94.2) 66 (5.8) 1 n=2328   
Wales 366 (94.1) 23 (5.9) 1.01 (0.62–1.65)   
NI 161 (91.5) 15 (8.5) 1.50 (0.84–2.7)   
RoI 594 (94) 38 (6%) 1.03 (0.68–1.56)   
Age 
18–25 355 (94.9) 19 (5.1) 1.33 (0.75–2.36) 1.11 (0.57–2.15) 
26–35 456 (92.9) 35 (7.1) 1.91 (1.18–3.09)** 1.65 (0.950–2.86) 
36–45 496 (90.3) 53 (9.7) 2.66 (1.71–4.13)*** 1.96 (1.18–3.26)* 
 46 871 (96.1) 35 (3.9) 1 n=2320 1  
Sexual Orientation 
Gay 1768 (93.5) 122 (6.5) 1 n=2305   
Other MSM 398 (95.9) 17 (4.1) 0.62 (0.37–1.04)   
Gender 
Transgender 120 (91.6) 11 (8.4%) 1 n=2296   
Male 2035 (94.0) 130 (6.0) 0.7 (0.37–1.33)   
Highest qualifications 
 Age 18 or equivalent 807 (94.5) 47 (5.5) 1 n=2287   
University Degree or 
equivalent 
986 (93.4) 70 (6.6) 1.22 (0.83–1.79)   
Postgraduate degree or 
higher 
353 (93.6) 24 (6.4) 1.17 (0.7–1.94)   
Relationship Status 
Single 1314 (92.7) 103 (7.3) 1.74 (1.19–2.54)** 1.83 (1.18–2.85)** 
Regular Partner 864 (95.7) 39 (4.3) 1 n=2320 1  
Do you have any financial worries? 
Occasionally or never 1268 (94.8) 70 (5.2) 1 n=2322 1  
Sometimes, most or all of 
the time 
 
912 (92.7) 72 (7.3) 1.43 (1.02–2.01)* 1.29 (0.86–1.92) 
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HIV Status 
HIV+ 139 (76) 44 (24) 6.55 (4.41–9.73)*** 4.01 (2.49–6.47)*** 
HIV-/Unknown 2007 (95.4) 97 (4.6) 1 n=2287 1  
Report High Risk CAI 
No 1438 (98) 30 (2) 1 n=2301 1  
Yes 725 (87) 108 (13) 7.14 (4.72–10.81)*** 4.46 (2.85–6.97)*** 
Have you been fisted in the last year? 
No 2081 (95.9) 90 (4.1) 1 n=2326 1  
Yes 103 (66.5) 52 (33.5) 11.67 (7.87–17.32)*** 7.77 (4.9–12.38)*** 
Have you been to a sex party / had group sex in the last year? 
No 1593 (97.5) 41 (2.5) 1 n=2322   
Yes 587 (85.3) 101 (14.7) 6.69 (4.59–9.73)***   
Have you received money in return for sex in the last year? 
No 2111 (94.1) 132 (5.9) 1 n=2297 1  
Yes 46 (85.2) 8 (14.8) 2.78 (1.29–6.01)** 1.56 (0.6–4.10) 
Have you had sex with someone in return for anything else (like cigarettes, drugs, food etc.) in the last year? 
No 2157 (94.3) 131 (5.7) 1 n=2322 1  
Yes 23 (67.6) 11 (32.4) 7.88 (3.76–16.5)*** 4.7 (1.67–13.21)** 
HIV test in the last year? 
No (includes never tested) 1090 (95.5) 51 (4.5) 1 n=2306   
Yes 1075 (92.3) 90 (7.7) 1.79 (1.26–2.55)**   
HIV test in the last 3 months? 
No (includes never tested) 1710 (95.4) 83 (4.6) 1 n=2306 1  
Yes 455 (88.7) 58 (11.3) 2.63 (1.85–3.73)*** 1.53 (1.02–2.3)* 
Discussion 
This is the first study of chemsex across Scotland, Wales, NI and RoI, and the first therein to 
distinguish chemsex drug use per se from its specific use within sexual contexts. Within this on-
line sample of MSM, we have demonstrated the low prevalence of chemsex drug use overall 
(8.2% within the previous 12 months), in contrast to the relatively high levels of illicit drug use at 
the individual level. Our study also indicates that not all chemsex drug use occurs within a sexual 
context, as more than a quarter (27.1%) of those who had used chemsex drugs reported no sex 
while under their influence. However, a quarter (25.9%) of those who had used chemsex drugs 
said that the majority of their sex occurred after taking them. Our findings clearly demonstrate 
that the use of drugs associated with chemsex is a minority behaviour across the UK, supporting 
research in England12, but expands our awareness of the proportion of sex that is had under their 
influence. 
While our findings suggest around one in seventeen (6.1%) MSM have engaged in chemsex 
within the last year, these men were more likely to be aged 36–45, single, report high risk CAI, 
report being fisted, report group sex, exchanging sex for non-financial benefits (e.g. cigarettes, 
drugs, food etc.) and an HIV positive status, providing clear targeting for intervention. It is also 
essential to acknowledge that while there may be a relatively low population prevalence of 
chemsex in the British Isles as a whole, it is likely that this behaviour is geographically 
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concentrated in large gay urban centers (e.g. Brighton, Manchester, London13). These high levels 
of associated risk taking and inequalities suggest the importance of early identification of those 
who may be most vulnerable to chemsex-related harm and the need to develop a specialised 
responsive patient pathway to address the specific needs of those who may benefit most from 
intervention. Our findings also suggest many of these men were already in touch with services, 
because of their HIV care or recent HIV testing history, meaning that existing sexual health 
services represent a suitable conduit for timely intervention. 
With regard to future intervention development, the findings here highlight several 
opportunities for further focused research. It is important to learn about those salutogenic factors, 
or assets, that enable most of men who engage with illicit drugs to avoid problematic drug use. 
Equally, for those who reported lifetime-use of chemsex drugs, understanding how they have 
maintained and managed episodic or one-off use, rather than continuous or repeated use, may 
inform interventions for problematic drug use. A thorough consideration of the pathways in and 
out of illicit drug use and sexualized drug use in particular may benefit the provision of culturally 
appropriate guidance for the wider MSM population. 
Whilst the relationship between chemsex and sexual risk taking is important to consider, we 
must acknowledge that our study design does not allow us to conclude that this is necessarily a 
causal relationship. Indeed, a wide variety of additional factors and inter-related health 
inequalities likely contribute to sexual risk taking and HIV/STI transmission within this 
context11,22. Thus, it is probable that other issues of vulnerability observed amongst MWEC 
herein (e.g. exchanging sex for cigarettes/drugs/food; financial worries), as well as other 
unrecorded issues, impact synergistically upon their sexual risk taking, necessitating a more 
holistic intervention than focusing just on sexualized drug taking. That MWEC were over four 
times more likely to report an HIV positive status suggests one means of targeting such men (e.g. 
within a clinical consultation) and higher rates of HIV testing suggest that HIV negative MWEC 
are at least aware of harm reduction in this context. However, as we measured neither PrEP use 
nor viral load in this study, we are unable to further comment on more sophisticated harm 
reduction behaviours. In addition, the relationship between chemsex and group sex provides the 
potential for sexual health and harm reductions to target sex party organisers, whilst the 
association with fisting raises the importance of promoting hepatitis C awareness amongst the gay 
community. 
A clear limitation of this study is that participants were sampled through gay sociosexual 
media, where most users are ostensibly seeking new sexual partners. Thus, this may represent a 
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more sexually active sample of MSM in these countries, at least in terms of seeking new sex 
partners, which may not be representative of men who do not use such sites. While problems of 
accessibility may exist for small proportions of the target population, recently published 
modelling indicates that online surveys of MSM in the UK can result in samples that are not 
significantly divergent from considerably more expensive venue-based sampling23. That said, 
83.2% of men in this sample reported using the commercial gay scene once a month or less, 
suggesting a minimal overlap with a venue-based study. It was not possible to calculate a 
response rate for these data, given the nature of online surveys and men’s use of multiple 
sites/profiles. However, the demographic profile and sexual behaviours of the sample achieved 
herein was comparable to other surveys of MSM (e.g. McDaid et al.20), which supports the wider 
generalizability of these data. A clear limitation is that our results rely on estimates of self-
reported behaviours, spanning the previous year, rather than any objective measure of behaviour. 
Moreover, we are relying on recall of drug-taking behaviours, which may themselves impact 
recall accuracy. Nevertheless, such self-report estimates are ubiquitous within online cross-
sectional surveys and no methods to provide more objective measures are available. Finally, our 
analyses and conclusions assume an at least partially causal relationship between chemsex, drug 
taking, sexual risk taking and demographic characteristics (which are themselves likely to be 
bidirectional relationships) which given the correlational nature of our cross-sectional study 
design must be interpreted with caution, though this generic criticism applies to much public 
health behavioural research. 
In observing the relatively small proportion of men who engage in chemsex, it is crucial that 
those funding, designing and delivering sexual health interventions for gay, bisexual and other 
MSM also recognise their particularly acute needs3. Recognising and understanding diverse 
motivations for engaging in chemsex is central to helping men manage their drug use and reduce 
the harms to themselves or others24. While not all MSM who engage in chemsex will experience 
difficulties, those that do require tailored harm reduction and psycho-therapeutic interventions. 
These should be positioned within broader programs that address syndemic health inequalities 
and support the holistic sexual health of gay, bisexual and other MSM, rather than focusing on 
singular issues or behaviours25. 
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